Rimonabant is a CB1 cannabinoid receptor antagonist which has been shown in animals to reduce alcohol consumption. This protocol is intended to determine if Rimonabant will decrease alcohol consumption in individuals who consume between 20 and 50 drinks of alcohol per week. To date, twenty participants have been enrolled in this double-blind study. Data analysis will not be preformed until the study is complete.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Intramural Research (Z01)
Project #
1Z01AA000208-03
Application #
7146650
Study Section
(LCS)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2005
Total Cost
Indirect Cost
Name
Alcohol Abuse and Alcoholism
Department
Type
DUNS #
City
State
Country
United States
Zip Code